-transparent.png){kind=logo}
In a pilot study, 18 patients with advanced ovarian cancer were evaluated for tolerance and response to a combination treatment with a fixed dose of carboplatin (350 mg/m2 given i.v. on day 1) and escalated doses of etoposide (70-130 mg/m2 daily given i.v. on days 1-3) as first-line chemotherapy. The maximum tolerated dose of etoposide was 130 mg/m2 when given i.v. on days 1-3 in combination with 350 mg/m2 carboplatin given i.v. every 4 weeks. At these dose levels, bone marrow toxicity was manageable and did not appear to be cumulative. In all, 12 objective responses, including 9 complete responses (CRs) and 3 partial responses (PRs), were achieved in 18 patients; 6 of the 9 CRs were confirmed as pathological CRs by second-look surgery.
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
November 1995,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
December 2006,
BJOG : an international journal of obstetrics and gynaecology,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
March 1999,
Praxis,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
October 2018,
European journal of pharmacology,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
November 1989,
British journal of cancer,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
September 1993,
Annals of oncology : official journal of the European Society for Medical Oncology,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
January 2001,
British journal of cancer,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
April 2005,
Gynecologic oncology,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
November 2004,
Journal of the National Cancer Institute,
W Eiermann, and
W Achterrath, and
L Lenaz, and
H Hepp
February 1987,
Cancer treatment reports,
